Comparison of initial intraocular pressure response with topical beta-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the Ocular Hypertension Treatment Study.
Comparison of initial intraocular pressure response with topical beta-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the Ocular Hypertension Treatment Study.
复制标题
DOI：
10.1001/archopht.125.4.454
复制
发表时间：
2007-04
影响因子：
--
通讯作者：
S. Mansberger;B. Hughes;M. Gordon;S. Spaner;J. Beiser;G. Cioffi;M. Kass
中科院分区：
文献类型：
--
作者：
S. Mansberger;B. Hughes;M. Gordon;S. Spaner;J. Beiser;G. Cioffi;M. Kass
目的比较高眼压治疗研究中自认为的非洲裔美国人和白色参与者与局部非选择性β-肾上腺素能拮抗剂或前列腺素类似物治疗试验的眼压（IOP）反应。方法采用校正了基线IOP和角膜厚度的多变量模型来估计不同种族的IOP反应。参与者包括536名接受局部β-肾上腺素能拮抗剂治疗的患者和191名接受前列腺素类似物治疗的患者，其中25%为非洲裔美国人。主要观察指标治疗试验4 ~ 6周后同侧眼的眼压反应。结果非裔美国人和白色受试者对非选择性β-肾上腺素能拮抗剂的眼压反应没有差异。非裔美国人受试者对前列腺素类似物的眼内压反应略大，但这种差异无统计学意义。对于这两类药物，更大的IOP降低与更高的基线IOP和更薄的中央角膜测量值相关。结论：我们发现自认为非裔美国人和白色人对局部非选择性β-肾上腺素能拮抗剂或前列腺素类似物的IOP反应无统计学显著差异。应用于IOP对药物反应的临床实践研究，应根据基线IOP和中央角膜厚度进行统计学调整。临床医生在为患者选择眼科治疗药物时，应考虑种族以外的因素。试验注册clinicaltrials.gov标识符：NCT 00000125。
OBJECTIVE To compare the intraocular pressure (IOP) responses of self-identified African American and white participants in the Ocular Hypertension Treatment Study to therapeutic trials of topical, nonselective beta-adrenergic antagonists or prostaglandin analogues. METHODS Multivariate models that adjusted for baseline IOP and corneal thickness were used to estimate IOP response by race. Participants included 536 who were prescribed topical beta-adrenergic antagonists and 191 who were prescribed prostaglandin analogues, 25% of whom were African American. MAIN OUTCOME MEASURE Intraocular pressure response in the ipsilateral eye after 4 to 6 weeks of a therapeutic trial. RESULTS Intraocular pressure response to nonselective beta-adrenergic antagonists did not differ between African American and white participants. Intraocular pressure response to prostaglandin analogues was slightly greater in African American participants, but this difference was not statistically significant. With both classes of medication, greater IOP reduction was associated with higher baseline IOP and thinner central corneal measurement. CONCLUSIONS We found no statistically significant differences in IOP response to topical, nonselective beta-adrenergic antagonists or prostaglandin analogues between self-identified African American and white individuals. Application to Clinical Practice Studies of IOP response to medication should statistically adjust for baseline IOP and central corneal thickness. Clinicians should consider factors other than ethnicity when choosing an ocular hypotensive medication for a patient. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00000125.